Release of high-sensitive TROPonin T by implantation of an entirely subcutaneous Implantable Cardioverter-defibrillator compared to a conventional transvenous approach: the TROPIC registry.
Defibrillation threshold testing
High-sensitive troponin T
Myocardial damage
Subcutaneous implantable cardioverter-defibrillator
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
14
05
2020
accepted:
10
09
2020
pubmed:
23
9
2020
medline:
5
10
2021
entrez:
22
9
2020
Statut:
ppublish
Résumé
Implantation of a subcutaneous implantable cardioverter-defibrillator (S-ICD) has become an alternative option when a conventional transvenous approach is not suitable. The myocardial damage caused by S-ICD implantation appears to be minimal despite mandatory defibrillation threshold (DFT) testing. However, there has not been a direct comparison with the traditional transvenous placement of a single-chamber ICD (VVI-ICD). The aim of this study was to determine the extent of myocardial damage by analysing the changes in serum levels of cardiac enzymes after S-ICD implantation in comparison with VVI-ICD. In 43 patients who received an S-ICD system, differences in serum levels of high-sensitive troponin T (ΔhsTnT) and creatine kinase total (ΔCK) and muscle brain fraction (ΔCK-MB) were acquired by blood sampling before and the day after implantation. The control group consisted of 43 patients from the TropShock study who had received a transvenous VVI-ICD without DFT. After S-ICD implantation and testing procedure, ΔhsTnT (0.000 ng/ml, IQR - 0.003-0.002 ng/ml) was significantly lower than after conventional VVI-ICD implantation (0.018 ng/ml, IQR 0.004-0.032 ng/ml; p < 0.001). There was no significant difference in CK (ΔCK S-ICD implantation causes less myocardial damage than VVI-ICD implantation evidenced by ΔhsTnT and ΔCK-MB.
Identifiants
pubmed: 32959177
doi: 10.1007/s10840-020-00874-z
pii: 10.1007/s10840-020-00874-z
doi:
Substances chimiques
Troponin T
0
Creatine Kinase, MB Form
EC 2.7.3.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-81Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Priori SG, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867.
doi: 10.1093/eurheartj/ehv316
Burke MC, Gold MR, Knight BP, Barr CS, Theuns DAMJ, Boersma LVA, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS Registry. J Am Coll Cardiol. 2015;65(16):1605–15.
doi: 10.1016/j.jacc.2015.02.047
Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363(1):36–44.
doi: 10.1056/NEJMoa0909545
Al-Khatib SM, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e73–e189.
doi: 10.1016/j.hrthm.2017.10.036
Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, al-Khatib SM, Almendral J, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2016;13(2):e50–86.
doi: 10.1016/j.hrthm.2015.11.018
Quast ABE, et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: the PRAETORIAN score. Heart Rhythm. 2019;16(3):403–10.
doi: 10.1016/j.hrthm.2018.09.029
Hurst TM, Hinrichs M, Breidenbach C, Katz N, Waldecker B. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol. 1999;34(2):402–8.
doi: 10.1016/S0735-1097(99)00194-1
Hasdemir C, et al. Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks. J Cardiovasc Electrophysiol. 2002;13(2):144–50.
doi: 10.1046/j.1540-8167.2002.00144.x
Schluter T, et al. Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage. Clin Chem. 2001;47(3):459–63.
doi: 10.1093/clinchem/47.3.459
Semmler V, Biermann J, Haller B, Jilek C, Sarafoff N, Lennerz C, et al. ICD shock, not ventricular fibrillation, causes elevation of high sensitive troponin T after defibrillation threshold testing--the prospective, randomized, Multicentre TropShock-Trial. PLoS One. 2015;10(7):e0131570.
doi: 10.1371/journal.pone.0131570
Blazek P, et al. Pacemaker implantation associated myocardial micro-damage: a randomised comparison between active and passive fixation leads. Sci Rep. 2018;8(1):4870.
doi: 10.1038/s41598-018-23209-5
D’Onofrio, A., et al. Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study. Europace 2018;20(FI2):f233–f9.
Knops RE, Olde Nordkamp LRA, de Groot JR, Wilde AAM. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2013;10(8):1240–3.
doi: 10.1016/j.hrthm.2013.05.016
Dworschak M, Franz M, Khazen C, Czerny M, Haisjackl M, Hiesmayr M. Mechanical trauma as the major cause of troponin T release after transvenous implantation of cardioverter/defibrillators. Cardiology. 2001;95(4):212–4.
doi: 10.1159/000047374
Furniss G, Shi B, Jimenez A, Harding SA, Larsen PD. Cardiac troponin levels following implantable cardioverter defibrillation implantation and testing. Europace. 2015;17(2):262–6.
doi: 10.1093/europace/euu306
Francis CK, et al. Brain natriuretic peptide and biomarkers of myocardial ischemia increase after defibrillation threshold testing. Pacing Clin Electrophysiol. 2012;35(3):314–9.
doi: 10.1111/j.1540-8159.2011.03275.x
Ishigaki D, Kutsuzawa D, Arimoto T, Iwayama T, Hashimoto N, Kumagai Y, et al. The association between defibrillation shock energy and acute cardiac damage in patients with implantable cardioverter defibrillators. J Arrhythm. 2016;32(6):481–5.
doi: 10.1016/j.joa.2016.03.007
Killingsworth CR, Melnick SB, Litovsky SH, Ideker RE, Walcott GP. Evaluation of acute cardiac and chest wall damage after shocks with a subcutaneous implantable cardioverter defibrillator in Swine. Pacing Clin Electrophysiol. 2013;36(10):1265–72.
pubmed: 23713608
pmcid: 3796010
Garcia R, Inal S, Favreau F, Jayle C, Hauet T, Bruneval P, et al. Subcutaneous cardioverter defibrillator has longer time to therapy but is less cardiotoxic than transvenous cardioverter defibrillator. Study carried out in a preclinical porcine model. Europace. 2018;20(5):873–9.
doi: 10.1093/europace/eux074
Al-Khatib SM, et al. Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol. 2008;1(4):240–9.
doi: 10.1161/CIRCEP.108.777888
Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, et al. Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry: the EFFORTLESS study. J Am Coll Cardiol. 2017;70(7):830–41.
doi: 10.1016/j.jacc.2017.06.040
Brouwer TF, Yilmaz D, Lindeboom R, Buiten MS, Olde Nordkamp LRA, Schalij MJ, et al. Long-term clinical outcomes of subcutaneous versus transvenous implantable defibrillator therapy. J Am Coll Cardiol. 2016;68(19):2047–55.
doi: 10.1016/j.jacc.2016.08.044
Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116(11):1242–9.
doi: 10.1161/CIRCULATIONAHA.106.655076
Nakamura Y, Yoshihisa A, Takiguchi M, Shimizu T, Yamauchi H, Iwaya S, et al. High-sensitivity cardiac troponin T predicts non-cardiac mortality in heart failure. Circ J. 2014;78(4):890–5.
doi: 10.1253/circj.CJ-13-1372
Pavasini R, d’Ascenzo F, Campo G, Biscaglia S, Ferri A, Contoli M, et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Cardiol. 2015;191:187–93.
doi: 10.1016/j.ijcard.2015.05.006
Blendea D, Blendea M, Banker J, McPherson CA. Troponin T elevation after implanted defibrillator discharge predicts survival. Heart. 2009;95(14):1153–8.
doi: 10.1136/hrt.2008.162677
Healey JS, Hohnloser SH, Glikson M, Neuzner J, Mabo P, Vinolas X, et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Lancet. 2015;385(9970):785–91.
doi: 10.1016/S0140-6736(14)61903-6
Bansch D, et al. The NO Regular Defibrillation testing In Cardioverter Defibrillator Implantation (NORDIC ICD) trial: concept and design of a randomized, controlled trial of intra-operative defibrillation testing during de novo defibrillator implantation. Europace. 2015;17(1):142–7.
doi: 10.1093/europace/euu161
Olde Nordkamp LR, et al. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J. 2012;163(5):753–760 e2.
doi: 10.1016/j.ahj.2012.02.012